Pretreatment ADC Values Predict Response to Radiosurgery in Vestibular Schwannomas

References

1. 1.↵
   2. Sinha S,
   3. Sharma BS

   . Cystic acoustic neuromas: surgical outcome in a series of 58 patients. J Clin Neurosci 2008;15:511–15 doi:10.1016/j.jocn.2007.01.007 pmid:18329881

   CrossRefPubMed
2. 2.↵
   2. Wandong S,
   3. Meng L,
   4. Xingang L, et al

   . Cystic acoustic neuroma. J Clin Neurosci 2005;12:253–55 doi:10.1016/j.jocn.2004.03.040 pmid:15851076

   CrossRefPubMed
3. 3.↵
   2. Benech F,
   3. Perez R,
   4. Fontanella MM, et al

   . Cystic versus solid vestibular schwannomas: a series of 80 grade III-IV patients. Neurosurg Rev 2005;28:209–13 doi:10.1007/s10143-005-0380-y pmid:15739069

   CrossRefPubMed
4. 4.↵
   2. Berkowitz O,
   3. Iyer AK,
   4. Kano H, et al

   . Epidemiology and environmental risk factors associated with vestibular schwannoma. World Neurosurg 2015;84:1674–80 doi:10.1016/j.wneu.2015.07.007 pmid:26171891

   CrossRefPubMed
5. 5.↵
   2. Asano K,
   3. Ebina K,
   4. Sekiya T, et al

   . Acoustic neurinomas with large cystic components: a clinical and pathological study of 3 cases. [Article in Japanese] No Shinkei Geka 1995;23:1075–82

   PubMed
6. 6.↵
   2. Kameyama S,
   3. Tanaka R,
   4. Kawaguchi T, et al

   . Cystic acoustic neurinomas: studies of 14 cases. Acta Neurochir (Wien) 1996;138:695–99 doi:10.1007/BF01411474 pmid:8836284

   CrossRefPubMed
7. 7.↵
   2. Stangerup SE,
   3. Caye-Thomasen P

   . Epidemiology and natural history of vestibular schwannomas. Otolaryngol Clin North Am 2012;45:257–68, vii doi:10.1016/j.otc.2011.12.008 pmid:22483814

   CrossRefPubMed
8. 8.↵
   2. Chuang CC,
   3. Chang CS,
   4. Tyan YS, et al

   . Use of apparent diffusion coefficients in evaluating the response of vestibular schwannomas to Gamma Knife surgery. J Neurosurg 2012;117:63–68 doi:10.3171/2012.7.GKS121003

   CrossRef
9. 9.↵
   2. Park CK,
   3. Kim DC,
   4. Park SH, et al

   . Microhemorrhage, a possible mechanism for cyst formation in vestibular schwannomas. J Neurosurg 2006;105:576–80 doi:10.3171/jns.2006.105.4.576 pmid:17044561

   CrossRefPubMed
10. 10.↵
    2. Chenevert TL,
    3. McKeever PE,
    4. Ross BD

    . Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997;3:1457–66 pmid:9815831

    Abstract
11. 11.↵
    2. Sawamura Y,
    3. Shirato H,
    4. Sakamoto T, et al

    . Management of vestibular schwannoma by fractionated stereotactic radiotherapy and associated cerebrospinal fluid malabsorption. J Neurosurg 2003;99:685–92 doi:10.3171/jns.2003.99.4.0685 pmid:14567604

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Godefroy WP,
    3. van der Mey AG,
    4. de Bruine FT, et al

    . Surgery for large vestibular schwannoma: residual tumor and outcome. Otol Neurotol 2009;30:629–34 doi:10.1097/MAO.0b013e3181a8651f pmid:19471168

    CrossRefPubMed
13. 13.↵
    2. Link MJ,
    3. Driscoll CL,
    4. Foote RL, et al

    . Radiation therapy and radiosurgery for vestibular schwannomas: indications, techniques, and results. Otolaryngol Clin North Am 2012;45:353–66, viii–ix doi:10.1016/j.otc.2011.12.006 pmid:22483821

    CrossRefPubMed
14. 14.↵
    2. Gerganov VM,
    3. Samii M

    . Giant vestibular schwannomas. World Neurosurg 2012;77:627–28 doi:10.1016/j.wneu.2011.10.008 pmid:22120232

    CrossRefPubMed
15. 15.↵
    2. Paldor I,
    3. Chen AS,
    4. Kaye AH

    . Growth rate of vestibular schwannoma. J Clin Neurosci 2016;32:1–8 doi:10.1016/j.jocn.2016.05.003 pmid:27450283

    CrossRefPubMed
16. 16.↵
    2. Charabi S,
    3. Tos M,
    4. Børgesen SE, et al

    . Cystic acoustic neuromas. Results of translabyrinthine surgery. Arch Otolaryngol Head Neck Surg 1994;120:1333–38 doi:10.1001/archotol.1994.01880360031006 pmid:7980897

    CrossRefPubMed
17. 17.↵
    2. Charabi S,
    3. Thomsen J,
    4. Mantoni M, et al

    . Acoustic neuroma (vestibular schwannoma): growth and surgical and nonsurgical consequences of the wait-and-see policy. Otolaryngol Head Neck Surg 1995;113:5–14 doi:10.1016/S0194-5998(95)70138-9 pmid:7603722

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Kameyama S,
    3. Tanaka R,
    4. Honda Y, et al

    . The long-term growth rate of residual acoustic neurinomas. Acta Neurochir (Wien) 1994;129:127–30 doi:10.1007/BF01406491 pmid:7847152

    CrossRefPubMed
19. 19.↵
    2. Bakkouri WE,
    3. Kania RE,
    4. Guichard JP, et al

    . Conservative management of 386 cases of unilateral vestibular schwannoma: tumor growth and consequences for treatment. J Neurosurg 2009;110:662–69 doi:10.3171/2007.5.16836 pmid:19099381

    CrossRefPubMed
20. 20.↵
    2. Le Bihan D,
    3. Breton E,
    4. Lallemand D, et al

    . Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168:497–505 doi:10.1148/radiology.168.2.3393671 pmid:3393671

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Lu S,
    3. Ahn D,
    4. Johnson G, et al

    . Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors. AJNR Am J Neuroradiol 2003;24:937–41 pmid:12748097

    Abstract/FREE Full Text
22. 22.↵
    2. Baehring JM,
    3. Bi WL,
    4. Bannykh S, et al

    . Diffusion MRI in the early diagnosis of malignant glioma. J Neurooncol 2007;82:221–25 doi:10.1007/s11060-006-9273-3 pmid:17029014

    CrossRefPubMed
23. 23.↵
    2. Hwang EJ,
    3. Cha Y,
    4. Lee AL, et al

    . Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging. J Neurooncol 2013;112:427–35 doi:10.1007/s11060-013-1072-z pmid:23417358

    CrossRefPubMed
24. 24.↵
    2. Ignjatović J,
    3. Stojanov D,
    4. Zivković V, et al

    . Apparent diffusion coefficient in the evaluation of cerebral gliomas malignancy. Vojnosanit Pregl 2015;72:870–75 doi:10.2298/VSP140229073I pmid:26665552

    CrossRefPubMed
25. 25.↵
    2. Plotkin SR,
    3. Halpin C,
    4. Blakeley JO, et al

    . Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 2009;93:61–77 doi:10.1007/s11060-009-9867-7 pmid:19430883

    CrossRefPubMed
26. 26.↵
    2. Schneider T,
    3. Chapiro J,
    4. Lin M, et al

    . 3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma. Eur Radiol 2016;26:849–57 doi:10.1007/s00330-015-3895-9 pmid:26139318

    CrossRefPubMed
27. 27.↵
    2. Landis JR,
    3. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 doi:10.2307/2529310 pmid:843571

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Myrseth E,
    3. Møller P,
    4. Pedersen PH, et al

    . Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery 2009;64:654–63; discussion 661–63 doi:10.1227/01.NEU.0000340684.60443.55 pmid:19197222

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Roche PH,
    3. Noudel R,
    4. Régis J

    . Management of radiation/radiosurgical complications and failures. Otolaryngol Clin North Am 2012;45:367–74, ix doi:10.1016/j.otc.2011.12.007 pmid:22483822

    CrossRefPubMed
30. 30.↵
    2. Wangerid T,
    3. Bartek J Jr.,
    4. Svensson M, et al

    . Long-term quality of life and tumour control following gamma knife radiosurgery for vestibular schwannoma. Acta Neurochir 2014;156:389–96 doi:10.1007/s00701-013-1924-5 pmid:24193890

    CrossRefPubMed
31. 31.↵
    2. Fuss M,
    3. Debus J,
    4. Lohr F, et al

    . Conventionally fractionated stereotactic radiotherapy (FSRT) for acoustic neuromas. Int J Radiat Oncol Biol Phys 2000;48:1381–87 doi:10.1016/S0360-3016(00)01361-4 pmid:11121637

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Litre F,
    3. Rousseaux P,
    4. Jovenin N, et al

    . Fractionated stereotactic radiotherapy for acoustic neuromas: a prospective monocenter study of about 158 cases. Radiot Oncol 2013;106:169–74 doi:10.1016/j.radonc.2012.10.013 pmid:23219253

    CrossRefPubMed
33. 33.↵
    2. Mohyuddin A,
    3. Vokurka EA,
    4. Evans DG, et al

    . Is clinical growth index a reliable predictor of tumour growth in vestibular schwannomas? Clin Otolaryngol Allied Sci 2003;28:85–90 doi:10.1046/j.1365-2273.2003.00670.x pmid:12680824

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Herwadker A,
    3. Vokurka EA,
    4. Evans DGR, et al

    . Size and growth rate of sporadic vestibular schwannoma: predictive value of information available at presentation. Otol Neurotol 2005;26:86–92 doi:10.1097/00129492-200501000-00015 pmid:15699725

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Hayhurst C,
    3. Zadeh G

    . Tumor pseudoprogression following radiosurgery for vestibular schwannoma. Neuro Oncol 2012;14:87–92 doi:10.1093/neuonc/nor171 pmid:22028389

    Abstract/FREE Full Text
36. 36.↵
    2. Pollock BE,
    3. Lunsford LD,
    4. Kondziolka D, et al

    . Vestibular schwannoma management. Part II. Failed radiosurgery and the role of delayed microsurgery. J Neurosurg 1998;89:949–55 doi:10.3171/jns.1998.89.6.0949 pmid:9833821

    CrossRefPubMed
37. 37.↵
    2. Pollock BE

    . Management of vestibular schwannomas that enlarge after stereotactic radiosurgery: treatment recommendations based on a 15 year experience. Neurosurgery 2006;58:241–47 discussion 241–48 doi:10.1227/01.NEU.0000194833.66593.8B pmid:16462477

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Yu CP,
    3. Cheung JY,
    4. Leung S, et al

    . Sequential volume mapping for confirmation of negative growth in vestibular schwannomas treated by gamma knife radiosurgery. J Neurosurg 2000;93(Suppl 3):82–89 doi:10.3171/jns.2000.93.supplement pmid:11143269

    CrossRefPubMed
39. 39.↵
    2. Nagano O,
    3. Higuchi Y,
    4. Serizawa T, et al

    . Transient expansion of vestibular schwannoma following stereotactic radiosurgery. J Neurosurg 2008;109:811–16 doi:10.3171/JNS/2008/109/11/0811 pmid:18976069

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Friedman RA,
    3. Brackmann DE,
    4. Hitselberger WE, et al

    . Surgical salvage after failed irradiation for vestibular schwannoma. Laryngoscope 2005;115:1827–32 doi:10.1097/01.mlg.0000175063.76945.75 pmid:16222204

    CrossRefPubMed
41. 41.↵
    2. Limb CJ,
    3. Long DM,
    4. Niparko JK

    . Acoustic neuromas after failed radiation therapy: challenges of surgical salvage. Laryngoscope 2005;115:93–98 doi:10.1097/01.mlg.0000150686.93011.49 pmid:15630374

    CrossRefPubMed
42. 42.↵
    2. Yang D,
    3. Korogi Y,
    4. Sugahara T, et al

    . Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiol 2002;44:656–66 doi:10.1007/s00234-002-0816-9 pmid:12185543

    CrossRefPubMed
43. 43.↵
    2. Ellingson BM,
    3. Timothy F,
    4. Cloughesy TF, et al

    . Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2011;105:91–101 doi:10.1007/s11060-011-0567-8 pmid:21442275

    CrossRefPubMed
44. 44.↵
    2. Nakamura H,
    3. Murakami R,
    4. Hirai T, et al

    . Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy? Acta Radiol 2013;54:214–20 doi:10.1258/ar.2012.120525 pmid:23138021

    CrossRefPubMed
45. 45.↵
    2. Kauppinen RA

    . Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed 2002;15:6–17 doi:10.1002/nbm.742 pmid:11840548

    CrossRefPubMed